Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 400-404

  Watanabe, Toru ^b   Iwasaki, Minoru ^a   Todaka, Takashi ^a   Morikawa, Hiroshi ^b   Ohtawa, Masakatsu ^b  

^a Panapharm Laboratories Co Ltd   (Japan)

^b Sandoz Pharmaceuticals Ltd   (Japan)

Author keywords

Multidrug resistance; P glycoprotein; Pharmacokinetic interaction; Protein binding; SDZ PSC 833

Indexed keywords

CYCLOSPORIN DERIVATIVE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; VALSPODAR; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; CONTROLLED STUDY; DRUG INTERACTION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031011138     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00015     Document Type: Article

References (23)

1. Chin K-V, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157-80.
2. Tsuruo T. Mechanism of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79: 285-96.
3. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
4. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629-35.
5. McLeod HL. Clinical reversal of the multidrug resistance phenotype: true tumor modulation or pharmacokinetic interaction? Eur J Cancer 1994; 30A: 2039-41.
6. Gordon TM, Brodie MJ. Drug interaction that matter a critical reappraisal. Drugs 1988; 36: 83-110.
7. D'Arcy PF, McElnay JC. Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites. Pharmacol Thera 1982; 17: 211-20.
8. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
9. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991; 2: 225-34.
10. Archinal-Mattheis A, Rzepka RW, Watanabe T, et al. Analysis of the interaction of SDZ PSC 833 ([3′-keto-Bmt1]-[Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995; 7: 603-10.
11. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor E In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res 1991; 51: 4226-33.
12. Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic- and solid-tumor-bearing mice models. Jpn J Cancer Res 1996; 87: 184-93.
13. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433-8.
14. Gonzalez O, Colombo T, Fusco MD, Imperatori L, Zucchetti M, D'Incalci M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 1995; 36: 335-40.
15. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-8.
16. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. J Pharm Pharmacol 1987; 39: 599-603.
17. Watanabe T, Suzuki H, Sawada Y, et al. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol 1995; 23: 440-8.
18. Legg B, Rowland M. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. Pharmac Res 1988; 5: 80-5.
19. Watanabe T, Miyauchi S, Sawada Y, et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 1992; 16: 77-88.
20. Stapf V, Thalhammer T, Huber-Huber R, Felberbauer F, Gajdzik L, Graf J. Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. Anticancer Res 1994; 14: 581-6.
21. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
22. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Brost P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-705.
23. 1,-acid glycoprotein. Eur J Cancer 1993; 29A: 559-61.